A2 BIO

Serial Number 97980850
748

Registration Progress

Application Filed
Oct 14, 2021
Under Examination
May 30, 2023
Approved for Publication
Apr 4, 2023
Published for Opposition
Apr 4, 2023
Registered

Trademark Image

A2 BIO

Basic Information

Serial Number
97980850
Filing Date
October 14, 2021
Published for Opposition
April 4, 2023
Drawing Code
3

Status Summary

Current Status
Active
Status Code
748
Status Date
Nov 10, 2025
Application
Pending
Classes
005 040 042

Rights Holder

A2 Biotherapeutics, Inc.

03
Address
30301 Agoura Road, Suite 210
Agoura Hills, CA 91301

Ownership History

A2 Biotherapeutics, Inc.

Original Applicant
03
Agoura Hills, CA

A2 Biotherapeutics, Inc.

Owner at Publication
03
Agoura Hills, CA

Legal Representation

Attorney
Joi A. White

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

42 events
Date Code Type Description Documents
Nov 11, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 10, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 30, 2025 IUAF S USE AMENDMENT FILED Loading...
Nov 10, 2025 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
May 30, 2025 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
May 30, 2025 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Nov 7, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 30, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
May 20, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 20, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
May 19, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
May 19, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 7, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 7, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 7, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Nov 7, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 15, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 14, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 14, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
May 14, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 21, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 17, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 17, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 17, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 30, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 4, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 4, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 15, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 25, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 24, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 23, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 23, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 22, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 22, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 22, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 20, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 13, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 13, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 13, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Nov 4, 2021 MDSM E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Nov 3, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 18, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer; biotherapeutics for the treatment and prevention of cancer; medicines for the treatment and prevention of cancer; pharmaceutical products for the treatment and prevention of cancer; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy products, namely, genetically engineered tissues for transplant purposes;
First Use Anywhere: May 1, 2023
First Use in Commerce: May 1, 2023
Class 040
Custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer;
First Use Anywhere: May 1, 2023
First Use in Commerce: May 1, 2023
Class 042
Medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of therapeutic targets for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for treatment and prevention of cancer; research and development of therapeutics and cell therapies targeting targets lost for the treatment and prevention of cancer; biotechnology research, development, testing and analysis for the treatment of cancer; scientific research and development services; providing scientific information relating to treatment and prevention of cancer; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services;
First Use Anywhere: May 1, 2023
First Use in Commerce: May 1, 2023

Additional Information

Design Mark
The mark consists of a black square with white frame and black border containing "A2" in white text in the lower right quadrant, with the word BIO in black text appearing under the number 2 and breaking the black and white border.
Pseudo Mark
A TWO BIO

Classification

International Classes
005 040 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIO"